the antiviral Treatment with interferon can significantly accelerate recovery from a coronavirus. This is the conclusion reached by the authors of a study from America and China, which conducted a study of the disease in 77 volunteers with a confirmed diagnosis COVID-19. The results published in Frontiers in Immunology.

the New virus remains in the body of patients is about twenty days from the moment of infection, and synthetic FN interferon-alpha-2b used to treat hepatitis and cancer, have reduced the time by about a week. And was effective regardless of patient age.

Proteins-interferons – these are some of the key signaling molecules of the immune system that are produced in response to viral and bacterial infections, the first line of protection against any virus, by definition, Dr. Eleanor fish from the research Institute and the University General hospital of Toronto. Interferons do not give the virus to multiply in infected cells and fight against pathogens.

the Object of the study were 77 people, admitted to hospital in Wuhan hospital in the period from 16 January to 20 February 2020. They have seen the initial symptoms of the disease, including fever, chills, cough, sore throat, headache, nasal discharge, myalgia, fatigue, dyspnea and diarrhea. They have volunteered to receive the experimental drug – a synthetic interferon. Each patient was asked to determine the date of onset of symptoms.

during the period of treatment they received abolitionary IFN-a2b, or a combination of IFN-a2b plus Arbidol. Each patient during his hospital stay were testing, doing blood tests, including cell count, biochemistry and levels of cytokines in serum, measured the temperature and level of blood oxygen saturation. All analyses were adjusted for age, gender and the presence of one or more comorbidities.

As scientists have found that treatment with IFN-a2b significantly reduced the detection time of the virus in the upper respiratory tract and in parallel reduced the duration of elevated blood levels of inflammation markers. This has led scientists to believe that interferon should be further explored as a therapy in cases COVID-19.

All patients underwent serial clinical studies. Regardless of treatment group, none of the patients in this group identified no persistent signs or symptoms organ dysfunction. In particular, none of the patients did not develop respiratory distress requiring prolonged oxygen Supplement or intubation. Consequently, none of the patients did not need intensive care. When about 50 percent of patients began to experience fever, the temperature rising above 38 degrees, managed to down ibuprofen. After this has been checkedmanufactures other outbreaks of fever irrespective of age and sex of the patients.

in addition, was conducted a serial of biochemical laboratory tests. In addition to easy increase of ALT during the early stages of hospitalization, which was subsequently improved in all patients, the data analyses showed that the levels fluctuate close to the normal range, with no clear differences between the treatment groups. Populations of peripheral blood cells was also measured during hospitalization, and were marked only on the increase in platelet count, all other tests were within normal limits.

Thus, clinical and laboratory data indicate a non-severe course of COVID-19 in all groups of patients. And application of FN interferon-Alfa-2b helps to cope with the coronavirus in a shorter time.

there were also fundamental differences in the analysis depending on the age, sex and concomitant diseases. With the exception of hemoglobin, which was lower in women.